Skip to content

Therapeutic effect and mechanism of ozonated autohemotherapy for patients with gout

Therapeutic effect and mechanism of ozonated autohemotherapy for patients with gout

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019612
Enrollment
Unknown
Registered
2018-11-19
Start date
2018-11-19
Completion date
Unknown
Last updated
2018-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gout

Interventions

Group 1:Ozone treatment of autologous blood
Group 2:Etoricoxib
Group 3:Ozone treatment of autologous blood and etoricoxib

Sponsors

Sir Run Run Hospital, Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Gout were established according to the diagnostic criteria for gout in the American College of Rheumatology; 2. Aged 18-60 years old; 3. The numerical rating scale (NRS) score of the joint is = 4 points.

Exclusion criteria

Exclusion criteria: 1. Systemic application of glucocorticoids, other immunosuppressive drugs or biological immunomodulators, antibiotics, probiotics and other microecological preparations within 6 months prior to enrollment; 2. Active infection (including human immunodeficiency virus (HIV), hepatitis B and hepatitis C virus infection or tuberculin test positive); 3. The affected joint also has rheumatoid arthritis, infectious arthritis or other arthritis; 4. Severe liver and kidney disease, history of peptic ulcer or bleeding, history of heart, cerebrovascular disease and blood system diseases; 5. Hyperthyroidism; 6. Havism; 7. Contraindications for NSAIDs; 8. Intra-articular hormone injection therapy in the past 4 weeks; 9. Pregnant or lactating woman; 10. Patients who are participating in other clinical trials; 11. Patients who suffer from mental illness, patients who are unwilling to receive ozonated autohemotherapy and researchers judged that the patients unsuitable for clinical trials.

Design outcomes

Primary

MeasureTime frame
uric acid;symptom;

Secondary

MeasureTime frame
blood lipid;blood glucose;BMI;Liver function;Kidney function;HbA1c;

Countries

China

Contacts

Public ContactLiu Yu

Sir Run Run Hospital, Nanjing Medical University

drliuyu@njmu.edu.cn+86 18751896699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026